Claims for Patent: 7,973,031

Summary for Patent: 7,973,031

Title:	Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Abstract:	The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.
Inventor(s):	Griffin; James Douglas (Brookline, MA), Manley; Paul William (Arlesheim, CH)
Assignee:	Novartis AG (Basel, CH) Dana-Farber Cancer Institute Inc (Boston, MA)
Application Number:	10/493,786
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,973,031
Patent Claims:	1. A method for treating a mammal suffering from acute myeloid leukemia comprising orally administering to a mammal in need of such treatment a therapeutically effective amount of up to 150 mg per day of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9- ,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiaz- onin-11-yl]-N-methylbenzamide of the formula (VII): ##STR00007## or a salt thereof. 2. A method according to claim 1, wherein the acute myeloid leukemia is characterized by deregulated FLT3 receptor tyrosine kinase activity. 3. A method according to claim 1, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion. 4. A method according to claim 3, wherein the compound of formula VII is administered as a microemulsion. 5. A method according to claim 2, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion. 6. A method according to claim 5, wherein the compound of formula VII is administered as a microemulsion.